Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Functional, structural and molecular characterization of a new mitral valve prolapse animal model : The FLNA-P637Q KI rat

Autor: Amir Hossein Kayvanjoo, T. Le Tourneau, S Blandin, R. Capoulade, Claire Toquet, I Anegon, S Remy, B. Lauzier, Jean-Jacques Schott, Elvira Mass, Jean Mérot, P. Aumond, J Veziers, C. Delwarde

Publikováno v: Archives of Cardiovascular Diseases Supplements. 14:60

Introduction Mitral Valve Prolapse (MVP) affects 3% of the population and is characterized by a heterogeneous mitral leaflet remodeling. The pathophysiological mechanisms involved in MVP development are not fully understood, the only therapeutic opti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b39ffd4a843537efb6f5ccc5aa10bcf
https://doi.org/10.1016/j.acvdsp.2021.09.127

Traitement de maintenance par nivolumab 240 mg mensuel chez les patients en réponse persistante après 2 ans d’induction par nivolumab bi-mensuel : résultats préliminaires d’efficacité et de toxicité

Autor: C. Dussopt, D. Arpin, S. Storme, F. Magne, L. Odier, L. Falchero, S. Blandin

Publikováno v: Revue des Maladies Respiratoires Actualités. 12:206

Introduction Le nivolumab en monotherapie 240 mg/15 j est reconnu comme le traitement de reference de 2e ligne du CPNPC de stade 4, quel que soit le statut PD-L1. Il n’existe pas de recommandation claire sur la poursuite du Nivolumab chez les long-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::305447acf8c302c87a428e8cd8c55cbd
https://doi.org/10.1016/j.rmra.2019.11.455

Targeted lung cancer screening selects individuals at high risk of cardiovascular disease

Autor: Tom Newton, Anna Walsham, John Howells, Denis Colligan, Haval Balata, James Whittaker, Richard Sawyer, Stuart Mellor, Peter Elton, Anita Macnab, Kathryn Slevin, Matthew Evison, Richard Booton, Elaine Smith, Anna Sharman, S. Blandin Knight, P. Barber, Christopher A. Miller, R. Duerden, Klaus L. Irion, Janet Tonge, Sarah Taylor, Devinda Karunaratne, Sara Waplington, Melanie Greaves, P.A.J. Crosbie, Juliette Novasio, M. Kirwan, Ben Taylor, Emma J Crosbie

Publikováno v: Balata, H, Knight, S, Barber, P, Colligan, D, Crosbie, E, Duerdan, R, Elton, P, Evison, M, Greaves, M, Howells, J, Irion, K, Karunaratne, D, Kirwan, M, Macnab, A, Mellor, S, Miller, C, Newton, T, Novasio, J, Sawyer, R, Sharman, A, Slevin, K, Smith, E, Taylor, B, Taylor, S, Tonge, J, Walsham, A, Waplington, S, Whittaker, J, Booton, R & Crosbie, P 2018, ' Targeted lung cancer screening selects individuals at high risk of cardiovascular disease. ', Lung Cancer, vol. 124, pp. 148-153 . https://doi.org/10.1016/j.lungcan.2018.08.006, https://doi.org/10.1016/j.lungcan.2018.08.006

Background: Cardiovascular disease (CVD) is a major cause of morbidity and mortality in populations eligible for lung cancer screening. The aim of this study was to determine whether a brief CV risk assessment, delivered as part of a targeted communi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b74a56945ad9c0589a7003399f0a2446
https://pubmed.ncbi.nlm.nih.gov/30268454